FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
What happened
FDA reviewed records Omni Lens submitted in response to the agency's November 21, 2023, and April 5, 2024, requests under section 704(a)(4) of the FD&C Act. FDA found significant current good manufacturing practice (CGMP) violations: the firm lacked an adequate quality unit (the group responsible for quality oversight), delegated quality responsibilities to contract manufacturers, and did not adequately oversee a contract manufacturer whose aseptic processing room for ophthalmic drops was inadequately designed and lacked dynamic airflow visualization studies and specified effectiveness testing for benzalkonium chloride. FDA also found that Green Glo, BioGlo, and Vista Gonio Eye Lubricant were made at establishments not duly registered with FDA, making them misbranded (legally mislabeled).
What FDA found
The quality control unit failed to ensure drug products complied with CGMP and met established specifications for identity, strength, quality, and purity.
21 CFR 211.22The firm lacked an adequate quality unit and delegated its quality-unit responsibilities to contract manufacturers, leaving insufficient oversight of their CGMP compliance.
21 CFR 211.22Its contract manufacturer lacked an adequately designed aseptic processing (sterile manufacturing) room for ophthalmic drop products and had not performed dynamic airflow visualization studies for aseptic processing.
21 CFR parts 210 and 211The firm had not performed (b)(4) effectiveness testing for benzalkonium chloride-containing ophthalmic products.
21 CFR parts 210 and 211Green Glo, BioGlo, and Vista Gonio Eye Lubricant were manufactured at establishments that were not duly registered with FDA, so they are misbranded.
FD&C Act §502(o); §510; 21 U.S.C. 352(o), 360
What FDA wants
FDA tells Omni Lens to correct the violations promptly and respond in writing within 15 working days with corrective actions and a quality-unit assessment/remediation plan. FDA also says it may withhold approvals and continue refusing admission while the firm remains on Import Alert 66-40.
Who should pay attention
- brands that use Omni Lens or its contract manufacturers for ophthalmic OTC drugs
- distributors and importers of Green Glo, BioGlo, or Vista Gonio Eye Lubricant
- companies relying on contract manufacturers for sterile ophthalmic products
This is a summary. Read the original letter on fda.gov.